Cures Are Built
Cancer dynamics are modeled. System‑level interactions are simulated. Precise trials are developed. Treatment regimens are created. Patient care is reimagined. In this way, we believe CURES ARE BUILT
The approval by the FDA, on October 22, 2015, was a pivotal milestone for Merrimack. We are grateful for the many patients, clinicians, researchers and partners who helped bring ONIVYDE to this point. Thank you.
Click here for full prescribing information, including Boxed WARNING.
With 5 candidates in clinical trials, several in preclinical development, and multiple clinical-stage tools designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry.
Because tumors within the same cancer type vary greatly, a one-size-fits-all approach to treatment cannot always work. Merrimack’s investigational products are precisely engineered, and our clinical trials are developed with a singular focus on the patient population most likely to benefit.
Merrimack seeks to transform the integration of precision diagnostics and treatment regimens comprised of novel therapies. The manner in which we support the oncology community must change too.
We hail from diverse backgrounds, both personally and professionally. Yet we share a goal of building cures. Creativity sets our path. Patient, determined steps carry us forward.